Suzuken CoTSE:9987 +0.12%77 EBITDA Margin % is 3.72% as of Mar. 2026, which is 76% above its 10-year median of 2.11. GuruFocus rates TSE:9987 with a GF Score™ of 77/100 and a GF Value™ of 円5,907.58 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 119 Medical Distribution companies, Suzuken Co ranks worse than 66.39% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Suzuken Co's EBITDA for the
three
months ended in Mar. 2026 was 円22,384 Mil. Suzuken Co's Revenue for the
three
months ended in Mar. 2026 was 円601,017 Mil. Therefore, Suzuken Co's EBITDA margin for the quarter that ended in Mar. 2026 was 3.72%.
Suzuken Co (TSE:9987) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Suzuken Co EBITDA Margin % Related Terms
Suzuken Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Suzuken Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:9987 vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Suzuken Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzuken Co EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Suzuken Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Suzuken Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzuken Co (TSE:9987) has a EBITDA Margin % of 3.72% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Suzuken Co and its competitors. This is 76% above median its historical median of 2.11. Over the past decade, Suzuken Co's EBITDA Margin % has ranged from 1.07 to 2.68. According to the industry distribution chart, Suzuken Co ranks #79 out of 119 companies in the Medical Distribution industry, placing it in the top 66.4%.
Is Suzuken Co's EBITDA Margin % too high?
Suzuken Co's current EBITDA Margin % of 3.72% is 76% above median its 10-year median of 2.11. Over the past 10 years, this metric has ranged from a low of 1.07 to a high of 2.68. The Medical Distribution industry median EBITDA Margin % is 4.31. Suzuken Co's value of 3.72% is 13.7% below this industry median. Based on the distribution chart, Suzuken Co ranks #79 out of 119 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Suzuken Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzuken Co's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Suzuken Co ranks #79 out of 119 companies for EBITDA Margin %. This places Suzuken Co in the lower half of its industry. The industry median EBITDA Margin % is 4.31. Suzuken Co's value of 3.72% is 13.7% below this benchmark. Historically, Suzuken Co's own EBITDA Margin % has ranged from 1.07 to 2.68 over the past decade. While the company's 10-year median is 2.11 vs. the industry median of 4.31, Suzuken Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzuken Co's current EBITDA Margin % of 3.72% is 13.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Suzuken Co and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzuken Co's current EBITDA Margin % is 3.72%, which is 76% above median its own 10-year median of 2.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzuken Co stock overvalued right now?
Based on GuruFocus' analysis, Suzuken Co (TSE:9987) is currently considered Modestly Undervalued. The stock's GF Value™ is 円5,907.58, compared to a current price of 円4,976.00 — trading 15.8% below its estimated fair value. The current EBITDA Margin % is 3.72%, which is 76% above median its 10-year median of 2.11 and 13.7% below the Medical Distribution industry median of 4.31. Suzuken Co's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Suzuken Co (TSE:9987), the current EBITDA Margin % is 3.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzuken Co (TSE:9987) Overvalued in 2026?
Based on GuruFocus' analysis, Suzuken Co stock appears to be undervalued.
The current stock price of 円4,976.00 is trading 15.8% below its estimated GF Value™ of 円5,907.58.
GuruFocus considers Suzuken Co to be Modestly Undervalued.
Key valuation signals for TSE:9987:
EBITDA Margin %: 3.72% (76% above median its 10-year median of 2.11)
GF Value™: 円5,907.58 vs. price of 円4,976.00 (15.8% below fair value)
Industry Position: 13.7% below the Medical Distribution median (#79 of 119)
No single metric tells the full story. See the TSE:9987 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzuken Co Ltd is engaged in the manufacture and sale of pharmaceuticals and medical devices, and in providing insurance, pharmacy, and nursing care services. The company operates through segments, including Pharmaceutical Wholesale business, Healthcare product development business, Specialty Pharmaceuticals Distribution business, Regional medical nursing care support business, and Medical-related Services business. It generates the majority of its revenue from the Pharmaceutical Wholesale Business segment, which sells prescription pharmaceuticals, diagnostic reagents, medical equipment, and medical supplies.
77GF Score
Get the complete analysis for TSE:9987
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9987 has been successfully added to your 
